Table 2 Characteristics of 135 individuals in the validation cohort
Characteristics | Brain metastasis (N = 32) | Liver metastasis (N = 40) | Locally advanced (N = 38) | Healthy controls (N = 25) |
|---|---|---|---|---|
Age group-no. (%) | ||||
 < 55 year | 7 (21.9%) | 14 (35.0%) | 6 (15.8%) | 7 (28.0%) |
 55–64 year | 19 (59.4%) | 13 (32.5%) | 14 (36.8%) | 10 (40.0%) |
 ≥ 65 year | 6 (18.7%) | 13 (32.5%) | 18(47.4%) | 8 (32.0%) |
 Median age (range)-year | 59 (35–78) | 59 (42–78) | 63 (45–78) | 58 (30–79) |
Gender | ||||
 Male-no. (%) | 21 (65.6%) | 27 (67.5%) | 27 (71.1%) | 17 (68.0%) |
 Female-no. (%) | 11 (34.4%) | 13 (32.5%) | 11 (28.9%) | 8 (32.0%) |
History of tobacco use-no. (%) | ||||
 Never | 15 (46.9%) | 17 (42.5%) | 11 (28.9%) | 10 (40.0%) |
 Previous and current | 15 (46.9%) | 21 (52.5%) | 26 (68.4%) | 14 (56.0%) |
 Unknown | 2 (6.2%) | 2 (5.0%) | 1 (2.7%) | 1 (4.0%) |
Histologic subtype-no. (%) | ||||
 Non-small cell lung cancer | 22 (68.8%) | 25 (62.5%) | 22 (57.9%) | – |
 Small cell lung cancer | 10 (31.2%) | 15 (37.5%) | 16 (42.1%) | – |